|
Erdafitinib
|
DB12147 |
[In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy [L5956, L5959]. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy [L5956, L5959].
Erdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation [L5956, L5959]. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world [F4372], the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions.
Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward [L5956, L5959].] |
|
Histapyrrodine
|
DB13479 |
|
|
Menatetrenone
|
DB12148 |
[Menatetrenone has been used in trials studying the treatment of Diabetes, Osteoporosis, Prediabetic State, and Hepatocellular Carcinoma.] |
|
S-3304
|
DB12149 |
[S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others.] |
|
Antimony pentasulfide
|
DB13473 |
|
|
Duligotuzumab
|
DB12142 |
[Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.] |
|
Tipepidine
|
DB13474 |
|
|
Rezatomidine
|
DB12143 |
[Rezatomidine has been used in trials studying the treatment of Fibromyalgia, Cystitis, Interstitial, Irritable Bowel Syndrome, and Diabetic Neuropathy, Painful.] |
|
BMS-275183
|
DB12144 |
[BMS-275183 has been used in trials studying the treatment of Tumors and Non-small Cell Lung Cancer.] |
|
Furazidin
|
DB13475 |
|
|
Diisopromine
|
DB13476 |
|
|
AZD-0328
|
DB12145 |
[AZD0328 has been used in trials studying the treatment and basic science of Schizophrenia and Alzheimer's Disease.] |
|
Cefodizime
|
DB13470 |
|
|
Nalfurafine
|
DB13471 |
|
|
Dilmapimod
|
DB12140 |
[Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others. Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}] |
|
Cyclofenil
|
DB13472 |
|
|
Gilteritinib
|
DB12141 |
[Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.[A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830]] |
|
Alphameprodine
|
DB01499 |
[Alphameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. The stereoisomer betameprodine is similarly classified, however alphameprodine is more widely used (both are referred to as Meprodine). Alphameprodine is a structural analogue of meperidine. It exerts physiological effects characteristic of opioids, such as analgesia, euphoria and sedation, as well as itching, nausea, and respiratory depression.] |
|
Aspartame
|
DB00168 |
[Flavoring agent sweeter than sugar, metabolized as phenylalanine and aspartic acid.] |
|
Alphamethadol
|
DB01498 |
|
